AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36539741 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardisation of family involvement practices
Number of subjects: 75
Study 36539753 — intervention group
Group type: EXPERIMENTAL
Intervention: Family web-based nutrition intervention
Number of subjects: 43
Study 36539753 — intervention group
Group type: COMPARATOR
Intervention: Web-based general nutrition guidelines (control)
Number of subjects: 43
Study 36539781 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic PEG tube placement
Number of subjects: 0
Study 36539781 — intervention group
Group type: COMPARATOR
Intervention: Reactive PEG tube placement
Number of subjects: 0
Study 36539791 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 supplementation
Number of subjects: 80
Study 36539791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 36539794 — intervention group
Group type: EXPERIMENTAL
Intervention: WORKWELL programme (job retention vocational rehabilitation)
Number of subjects: 0
Study 36539794 — intervention group
Group type: COMPARATOR
Intervention: Written self-help information only (control)
Number of subjects: 0
Study 36539810 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-mg dose of doxycycline
Number of subjects: 0
Study 36539810 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-mg antibiotic dose of doxycycline
Number of subjects: 0
Study 36539810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36539846 — intervention group
Group type: EXPERIMENTAL
Intervention: smartphone condition
Number of subjects: 240
Study 36539846 — intervention group
Group type: EXPERIMENTAL
Intervention: VR condition
Number of subjects: 240
Study 36539846 — intervention group
Group type: COMPARATOR
Intervention: active control condition
Number of subjects: 240
Study 36539857 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive transfer program for parents (includes an informative website, bi-annual online educational events, and transfer consultations)
Number of subjects: 62
Study 36539857 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 62
Study 36539897 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant- or insect-based protein from the intervention foods
Number of subjects: 80
Study 36539907 — intervention group
Group type: EXPERIMENTAL
Intervention: Central IV
Number of subjects: 158
Study 36539907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary (IC)
Number of subjects: 158
Study 36539907 — intervention group
Group type: COMPARATOR
Intervention: Peripheral IV
Number of subjects: 158
Study 36539913 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed delirium
Number of subjects: 1564
Study 36539913 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoactive delirium
Number of subjects: 1564
Study 36539913 — intervention group
Group type: COMPARATOR
Intervention: Non-delirious patients
Number of subjects: 1564
Study 36539949 — intervention group
Group type: EXPERIMENTAL
Intervention: DRP prevention bundle
Number of subjects: 769
Study 36539949 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmaceutical care (Control)
Number of subjects: 769
Study 36540016 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration during intramuscular injection
Number of subjects: 0
Study 36540016 — intervention group
Group type: COMPARATOR
Intervention: No aspiration during intramuscular injection
Number of subjects: 0
Study 36540034 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI (FFR ≤0.80)
Number of subjects: 562
Study 36540034 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI (diameter stenosis of >50%)
Number of subjects: 562
Study 36540034 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 562
Study 36540034 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 562
Study 36541117 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Radiotherapy (CMT)
Number of subjects: 1478
Study 36541117 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (C)
Number of subjects: 1478
Study 36541125 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition Universal Screening Tool (MUST) score
Number of subjects: 59
Study 36541125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Risk Index (NRI)
Number of subjects: 59
Study 36541125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Risk Score 2002 (NRS-2002)
Number of subjects: 59
Study 36541125 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Complication Index
Number of subjects: 59
Study 36541125 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 59
Study 36541125 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to restart enteral intake
Number of subjects: 59
Study 36541125 — intervention group
Group type: EXPERIMENTAL
Intervention: Time without enteral intake
Number of subjects: 59
Study 36541257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-stored platelets (1°C-6°C) with a maximum storage duration of 21 days
Number of subjects: 0
Study 36541257 — intervention group
Group type: COMPARATOR
Intervention: Standard room temperature-stored platelets (20°C-24°C) with a maximum storage duration of 7 days
Number of subjects: 0
Study 36541390 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart-shaped intrauterine balloon inserted immediately after hysteroscopic adhesiolysis, left in place for 7 days under antibiotic prophylaxis.
Number of subjects: 10
Study 36541390 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart-shaped intrauterine balloon
Number of subjects: 10
Study 36541393 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse laser
Number of subjects: 266
Study 36541393 — intervention group
Group type: COMPARATOR
Intervention: Standard threshold macular laser
Number of subjects: 266
Study 36541529 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled breath condensate (EBC)
Number of subjects: 82
Study 36541529 — intervention group
Group type: COMPARATOR
Intervention: Bronchial washes (BWs)
Number of subjects: 82
Study 36541529 — intervention group
Group type: COMPARATOR
Intervention: Bronchoalveolar lavages (BALs)
Number of subjects: 82
Study 36541643 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL) group
Number of subjects: 41
Study 36541643 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL) group (subgroup analysis from EFV)
Number of subjects: 41
Study 36541643 — intervention group
Group type: COMPARATOR
Intervention: EFV/PI group
Number of subjects: 41
Study 36541642 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma OPN (osteopontin) among WWH
Number of subjects: 20
Study 36541642 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma OPN among WWH
Number of subjects: 20
Study 36541642 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma OPN among the whole group and WWH
Number of subjects: 20
Study 36541642 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma OPN among WWH and WWOH
Number of subjects: 20
Study 36541647 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma osteopontin levels
Number of subjects: 0
Study 36541957 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib plus RICE/RVICI
Number of subjects: 51
Study 36541957 — intervention group
Group type: COMPARATOR
Intervention: RICE/RVICI
Number of subjects: 51
Study 36542081 — intervention group
Group type: EXPERIMENTAL
Intervention: CF1 (340 µg dexamethasone)
Number of subjects: 49
Study 36542081 — intervention group
Group type: EXPERIMENTAL
Intervention: CF2 (340 µg dexamethasone)
Number of subjects: 49
Study 36542086 — intervention group
Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa 20 mg/kg every other week for 6 months
Number of subjects: 22
Study 36542086 — intervention group
Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa 40 mg/kg every other week for 6 months
Number of subjects: 22
Study 36542086 — intervention group
Group type: COMPARATOR
Intervention: alglucosidase alfa (current stable dose) for 6 months
Number of subjects: 22
Study 36542136 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of fibrosis (F0, F1, F2)
Number of subjects: 169
Study 36542136 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe fibrosis
Number of subjects: 169
Study 36542136 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence and degree of fibrosis
Number of subjects: 169
Study 36542145 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystine
Number of subjects: 35
Study 36542145 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cysteine (tCys)
Number of subjects: 35
Study 36542145 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cystine
Number of subjects: 35
Study 36542204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (CR) - two cognitive trainings/week (Reha1)
Number of subjects: 48
Study 36542204 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor rehabilitation - two motor trainings/week (Reha3)
Number of subjects: 48
Study 36542204 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rehabilitation - one cognitive and one motor training/week (Reha2)
Number of subjects: 48
Study 36542257 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic diffractive trifocal intraocular lens (IOL) with double C-loop haptics
Number of subjects: 23
Study 36542261 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous terlipressin infusion (CONI), 4 mg/24 h for 5 days
Number of subjects: 110
Study 36542261 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus terlipressin (BOL), 2 mg every 4 h
Number of subjects: 110
Study 36542261 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous terlipressin infusion (CONI)
Number of subjects: 110
Study 36542261 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus terlipressin (BOL)
Number of subjects: 110
Study 36542260 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide
Number of subjects: 211
Study 36542287 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin peglispro
Number of subjects: 857
Study 36542287 — intervention group
Group type: COMPARATOR
Intervention: Current case report form (CRF)
Number of subjects: 857
Study 36542308 — intervention group
Group type: EXPERIMENTAL
Intervention: PVO-OS (0.025, 0.05, or 0.10 mg/mL)
Number of subjects: 36
Study 36542308 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo-to-match PVO-OS)
Number of subjects: 36
Study 36542382 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly structured exercise
Number of subjects: 357
Study 36542382 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly structured exercise
Number of subjects: 357
Study 36542382 — intervention group
Group type: COMPARATOR
Intervention: Usual care (advice only)
Number of subjects: 357
Study 36542401 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based self-management intervention (LiveWell)
Number of subjects: 205
Study 36542401 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 205
Study 36542425 — intervention group
Group type: EXPERIMENTAL
Intervention: JomPrEP app (clinic-integrated mobile health intervention)
Number of subjects: 0
Study 36542453 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic sunscreen
Number of subjects: 44
Study 36542453 — intervention group
Group type: COMPARATOR
Intervention: Organic sunscreen
Number of subjects: 44
Study 36542513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine manipulator
Number of subjects: 170
Study 36542513 — intervention group
Group type: COMPARATOR
Intervention: Curettage
Number of subjects: 170
Study 36542513 — intervention group
Group type: COMPARATOR
Intervention: Hysteroscopy
Number of subjects: 170
Study 36542596 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care model featuring a four-step comprehensive geriatric assessment (screening, multi-dimensional assessment, coordinated individualized care plan, follow-up)
Number of subjects: 0
Study 36542596 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach strategies
Number of subjects: 0
Study 36542596 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation costs
Number of subjects: 0
Study 36542689 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicompartmental knee arthroplasty (UKA)
Number of subjects: 99
Study 36542689 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 99
Study 36542692 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-Cav1 (prefusion) vaccine
Number of subjects: 0
Study 36542692 — intervention group
Group type: COMPARATOR
Intervention: MEDI7510 (postfusion) vaccine
Number of subjects: 0
Study 36542760 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 262
Study 36542760 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic primary pain (ICD-11 classification)
Number of subjects: 262
Study 36542760 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic widespread pain
Number of subjects: 262
Study 36542760 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific pain from the back
Number of subjects: 262
Study 36542760 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain caused by osteoarthritis
Number of subjects: 262
Study 36542760 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain caused by stroke
Number of subjects: 262
Study 36542826 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel) - 100 × 10^6 chimeric antigen receptor-positive T cells
Number of subjects: 184
Study 36542826 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 184
Study 36542826 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) - 3 cycles of platinum-based immunochemotherapy followed by high-dose chemotherapy and ASCT in responders
Number of subjects: 184
Study 36543503 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day ECG patch screening
Number of subjects: 0
Study 36543719 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital intervention (DI) for chronic low back pain for 12 weeks
Number of subjects: 560
Study 36544079 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 32
Study 36544079 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy adults)
Number of subjects: 32
Study 36544130 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic musculoskeletal pain (CMP) patients
Number of subjects: 969
Study 36544130 — intervention group
Group type: COMPARATOR
Intervention: No chronic musculoskeletal pain (no-CMP) patients
Number of subjects: 969
Study 36544130 — intervention group
Group type: EXPERIMENTAL
Intervention: CMP patients
Number of subjects: 969
Study 36544166 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 blood pressure measurement education sessions using WhatsApp
Number of subjects: 70
Study 36544166 — intervention group
Group type: COMPARATOR
Intervention: Routine education using traditional lecture
Number of subjects: 70
Study 36544184 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecanemab 10 mg/kg biweekly
Number of subjects: 856
Study 36544184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 856
Study 36544208 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care and peer-group support in an online instant messaging app (n=15)
Number of subjects: 33
Study 36544208 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=18)
Number of subjects: 33
Study 36544211 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intake of soybeans and flaxseeds (~ 200 mg of phytoestrogens) until surgery (approximately 6 weeks)
Number of subjects: 200
Study 36544211 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 200
Study 36544226 — intervention group
Group type: EXPERIMENTAL
Intervention: Score-based model for predicting severe vitamin D deficiency (SVDD)
Number of subjects: 662
Study 36544226 — intervention group
Group type: EXPERIMENTAL
Intervention: SVDD score based on multivariable logistic regression (MLR) model
Number of subjects: 662
Study 36544398 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone vaginal insert (DVI)
Number of subjects: 1107
Study 36544398 — intervention group
Group type: EXPERIMENTAL
Intervention: No oxytocin for labor progression
Number of subjects: 1107
Study 36544398 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin for induction
Number of subjects: 1107
Study 36544398 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin for augmentation
Number of subjects: 1107
Study 36544548 — intervention group
Group type: EXPERIMENTAL
Intervention: Frondanol
Number of subjects: 100
Study 36544548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 36544965 — intervention group
Group type: EXPERIMENTAL
Intervention: POSTi NLR values in infected group aged 0-4 years
Number of subjects: 26
Study 36544965 — intervention group
Group type: EXPERIMENTAL
Intervention: POSTi NLR values in infected group aged over 18 years
Number of subjects: 26
Study 36544965 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative NLR and PLR values
Number of subjects: 26
Study 36544965 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR values at first admission to the hospital
Number of subjects: 26
Study 36544965 — intervention group
Group type: COMPARATOR
Intervention: Control group (29 patients without CI infection)
Number of subjects: 26
Study 36545256 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopurine 6-thioguanine (6TG) treatment
Number of subjects: 1
Study 36545256 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1
Study 36545312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor treatment in patients with CYP3A4*22 and CYP3A5 genotypes
Number of subjects: 0
Study 36545312 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36545322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib and Trametinib
Number of subjects: 9
Study 36546322 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 577
Study 36546322 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 577
Study 36546346 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 2636
Study 36546351 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-Setting group (received health vouchers for meeting sleep goals)
Number of subjects: 225
Study 36546351 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 225
Study 36546402 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 3038
Study 36546402 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 3038
Study 36546422 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin and lenalidomide, specific dosages and duration not available
Number of subjects: 0
Study 36546453 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel)
Number of subjects: 113
Study 36546453 — intervention group
Group type: COMPARATOR
Intervention: Real-world clinical practice (RWCP)
Number of subjects: 113
Study 36546479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (4 μg/kg initial dose, followed by 2 μg/kg if needed)
Number of subjects: 1091
Study 36546479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 1091
Study 36546511 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative Learning (CL) intervention in schools
Number of subjects: 1890
Study 36546511 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative Learning (CL) intervention
Number of subjects: 1890
Study 36546588 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 0
Study 36546588 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36546623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative average VAI in quartiles (3-4 quartiles ≥2.6)
Number of subjects: 10132
Study 36546623 — intervention group
Group type: COMPARATOR
Intervention: Cumulative average VAI in quartiles (1-2 quartiles <2.6)
Number of subjects: 10132
Study 36546623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative average systolic blood pressure <130 mmHg
Number of subjects: 10132
Study 36546624 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dupilumab (300 mg)
Number of subjects: 239
Study 36546624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 36546624 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab every 2 weeks (300 mg)
Number of subjects: 239
Study 36546624 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 239
Study 36546626 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentiviral gene-corrected autologous CD34+ cells infusion
Number of subjects: 10
Study 36546625 — intervention group
Group type: EXPERIMENTAL
Intervention: BPaLM (bedaquiline, pretomanid, linezolid, and moxifloxacin) for 24 weeks
Number of subjects: 301
Study 36546625 — intervention group
Group type: COMPARATOR
Intervention: Standard-care regimen for 9-to-20 months
Number of subjects: 301
Study 36546651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotorasib
Number of subjects: 38
Study 36546659 — intervention group
Group type: EXPERIMENTAL
Intervention: Adagrasib monotherapy (600 mg orally twice daily)
Number of subjects: 76
Study 36546659 — intervention group
Group type: EXPERIMENTAL
Intervention: Adagrasib in combination with cetuximab (initial loading dose of 400 mg/m², followed by 250 mg/m² weekly or 500 mg/m² every 2 weeks)
Number of subjects: 76
Study 36547147 — intervention group
Group type: EXPERIMENTAL
Intervention: Linac-based SBRT on the prostate bed, total dose of 32.5 Gy in five fractions every other day.
Number of subjects: 30
Study 36547147 — intervention group
Group type: EXPERIMENTAL
Intervention: Linac-based SBRT on the prostate bed
Number of subjects: 30
Study 36547262 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior quadratus lumborum block (QLB) with 3.75 mg/ml ropivacaine 20 ml/side
Number of subjects: 39
Study 36547262 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia with ropivacaine
Number of subjects: 39
Study 36547262 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior quadratus lumborum block (QLB)
Number of subjects: 39